Strategies for Neuroprotection, Relapse Prevention, and Decreasing Mortality in the Patients with Schizophrenia



Date & Location
Monday, May 11, 2020, 12:00 AM - Tuesday, May 11, 2021, 11:59 PM

Credits
AMA PRA Category 1 Credits™ (1.00 hours), AMA PRA Category 1 Credits™ Designated (1.00 hours)

Target Audience
Specialties - Psychiatry and Behavioral Health
Professions - Certified Research Professional, Physician

Overview
Only a minority of patients with schizophrenia consistently adhere to their oral antipsychotics. Long-acting injectable (LAI) formulations of antipsychotics improve patient outcomes through both neuroprotection and improved adherence. To ensure that more patients with schizophrenia are offered the opportunity to take LAIs, clinicians who provide psychiatric care must possess accurate information about this important treatment option. In this activity, an expert faculty member will discuss the safety and tolerability of LAIs; their role in the treatment of first-episode psychosis, as well as later in the course of schizophrenia; the selection of an LAI; and strategies for discussing the option of LAIs with patients. Two patient cases will be presented to illustrate the use of LAIs in common clinical scenarios. 

Registration

To register, please go to: www.freecme.com

Launch date: 5/11/2020 - End date: 5/11/2021

There are no fees for participating in and receiving credit for this activity. Participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the post-test by recording the best answer to each question, and 4) complete the evaluation form.


Objectives
After completing this activity, the participant should be better able to:

  1. Describe the efficacy, safety, and tolerability profiles of LAI antipsychotics, including similarities and differences with oral formulations
  2. Distinguish between adherence levels for LAI vs oral antipsychotics
  3. Illustrate the benefits of LAI antipsychotics, particularly regarding neuroprotection
  4. Assess the role of LAI antipsychotics early in schizophrenia, including first-episode psychosis

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati, Medical Education Resources (MER) and CMEology. 

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this online activity for a maximum of 1 AMA PRA Category 1 Credit™.  Physicians should claim only the credits commensurate with the extent of their participation in the activity.

 

Additional Information
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the University of Cincinnati, Medical Education Resources, CMEology, and/or Alkermes, Inc. or Otsuka America Pharmaceutical, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.